CRISPR Therapeutics AG (CRSP) — Financial statements
Income statement, balance sheet, and cash flow for CRISPR Therapeutics AG — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 4↓90.0% | 35↓90.5% | 370↑84762.4% | 0.44↓100.0% | 913 | |
| Cost of Revenue | 233↑111.3% | 110↓15.4% | 130↑18.1% | 110↑9.0% | 101 | |
| Gross Profit | -229↓204.9% | -75↓131.4% | 240↑318.3% | -110↓113.5% | 812 | |
| Operating Expenses | ||||||
| R&D Expenses | 265↓17.3% | 321↓17.2% | 387↓16.1% | 462↑35.6% | 341 | |
| General & Administrative Expenses | 74↑0.8% | 73↓4.2% | 76↓25.7% | 102↑2.8% | 100 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 74↑0.8% | 73↓4.2% | 76↓25.7% | 102↑2.8% | 100 | |
| Other Expenses | 0.00↑100.0% | -2↓91.9% | -1↓58.3% | -0.76↑59.5% | -2 | |
| Operating Expenses | 339↓13.4% | 391↓15.4% | 462↓17.9% | 563↑28.5% | 438 | |
| Total Costs & Expenses | 572↑14.0% | 502↓15.4% | 593↓12.0% | 674↑24.8% | 540 | |
| Operating Results | ||||||
| Operating Income | -568↓21.8% | -467↓109.7% | -223↑66.9% | -673↓280.2% | 374 | |
| Depreciation & Amortization | 19↑1.1% | 19↓2.9% | 20↓17.9% | 24↑34.6% | 18 | |
| EBITDA | -549↓22.7% | -447↓120.7% | -203↑68.8% | -649↓265.8% | 391 | |
| EBIT | -568↓21.8% | -467↓109.7% | -223↑66.9% | -673↓280.2% | 374 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | -10↓109.3% | 104↑44.7% | 72↑216.9% | 23↑277.5% | 6 | |
| Income Before Tax | -578↓59.4% | -363↓140.6% | -151↑76.8% | -651↓271.4% | 380 | |
| Income Tax Expense | 4↑1.3% | 4↑24.2% | 3↑988.6% | -0.33↓117.4% | 2 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -582↓58.8% | -366↓138.4% | -154↑76.4% | -650↓272.2% | 378 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -582↓58.8% | -366↓138.4% | -154↑76.4% | -650↓272.2% | 378 | |
| Bottom-Line Net Income | -582↓58.8% | -366↓138.4% | -154↑76.4% | -650↓272.2% | 378 | |
| EPS (Basic) | -6.47↓49.1% | -4.34↓123.7% | -1.94↑76.8% | -8.36↓268.2% | 4.97 | |
| EPS (Diluted) | -6.47↓49.1% | -4.34↓123.7% | -1.94↑76.8% | -8.36↓277.9% | 4.70 | |
| Weighted Average Shares | 90↑6.6% | 84↑6.5% | 79↑1.9% | 78↑2.4% | 76 | |
| Weighted Average Diluted Shares | 90↑6.6% | 84↑6.5% | 79↑1.9% | 78↓3.3% | 80 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.